GENEDX HOLDINGS CORP.

NASDAQ: WGS (GeneDx Holdings Corp.)

Kemas kini terakhir: 28 Mar, 6:09AM

94.34

-2.10 (-2.18%)

Penutupan Terdahulu 96.44
Buka 97.33
Jumlah Dagangan 557,891
Purata Dagangan (3B) 1,039,573
Modal Pasaran 2,647,963,392
Harga / Jualan (P/S) 7.56
Harga / Buku (P/B) 9.83
Julat 52 Minggu
8.53 (-90%) — 115.60 (22%)
Tarikh Pendapatan 28 Apr 2025 - 2 May 2025
Margin Keuntungan -17.12%
Margin Operasi (TTM) 10.98%
EPS Cair (TTM) -1.94
Pertumbuhan Hasil Suku Tahunan (YOY) 66.60%
Jumlah Hutang/Ekuiti (D/E MRQ) 47.37%
Nisbah Semasa (MRQ) 3.61
Aliran Tunai Operasi (OCF TTM) -28.50 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 1.11 M
Pulangan Atas Aset (ROA TTM) -3.20%
Pulangan Atas Ekuiti (ROE TTM) -22.10%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Health Information Services (US) Bercampur Bercampur
Health Information Services (Global) Bercampur Bercampur
Stok GeneDx Holdings Corp. Menaik Menaik

AISkor Stockmoo

-1.6
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam -1.5
Volatiliti Harga -4.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata -1.60

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
WGS 3 B - - 9.83
TEM 7 B - - 152.50
HQY 7 B - 72.29 3.69
WAY 6 B - - 2.35
RCM 6 B - - 2.14
PRVA 3 B - 205.64 4.19

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

Sektor Healthcare
Industri Health Information Services
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 12.91%
% Dimiliki oleh Institusi 88.11%

Pemilikan

Nama Tarikh Syer Dipegang
Science & Technology Partners, L.P. 31 Dec 2024 401,000
Gagnon Securities Llc 31 Dec 2024 359,376
108.30108.3080.4080.4052.5052.5024.6024.60-3.30-3.30Harga Sasaran MedianQ2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
8.53 (-90%) — 115.60 (22%)
Median 80.00 (-15.20%)
Jumlah 1 Pegang
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Goldman Sachs 19 Feb 2025 80.00 (-15.20%) Pegang 111.31

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
08 Apr 2025 Pengumuman GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025
03 Apr 2025 Pengumuman GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication
20 Mar 2025 Pengumuman GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Mar 2025 Pengumuman Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
04 Mar 2025 Pengumuman GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
24 Feb 2025 Pengumuman Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
18 Feb 2025 Pengumuman GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
13 Feb 2025 Pengumuman GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
12 Feb 2025 Pengumuman GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
10 Feb 2025 Pengumuman GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
28 Jan 2025 Pengumuman GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
17 Jan 2025 Pengumuman GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Jan 2025 Pengumuman GeneDx Announces Preliminary 2024 Financial Results
Papar semua
99.2599.2589.4189.4179.5679.5669.7269.7259.8859.88Mar 28Mar 28Mar 31Mar 31Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4Apr 7Apr 7Apr 8Apr 8

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
6.0006.0004.0004.0002.0002.0000.0000.000-2.000-2.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda